GlassScriptPhysician profile
Garo Kalfayan
NPI 1114667086
$683.81
in general payments reported to CMS, 2019-2025
12 companies · $82.78 in 2025
The $82.78 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $143 · 2023: $244 · 2024: $214 · 2025: $82.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $541.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $540.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $164.63 | 2022-2023 | Jesduvroq, Benlysta |
| Astrazeneca Pharmaceuticals LP | $114.76 | 2024 | Airsupra |
| Amgen INC. | $89.01 | 2023-2024 | Repatha, Krystexxa |
| Travere Therapeutics, INC. | $73.15 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $53.77 | 2022-2025 | Voyxact |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.64 | 2022-2024 | Jardiance |
| Calliditas Therapeutics US INC. | $38.88 | 2025 | Tarpeyo |
| Kiniksa Pharmaceuticals International, Plc | $27.73 | 2024 | Arcalyst |
| Aurinia Pharma U.S., INC. | $25.49 | 2023 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $18.95 | 2025 | |
| Vapotherm INC | $17.94 | 2023 | Vapotherm |
| Abbvie INC. | $14.86 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Garo Kalfayan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.